featured
Impact of a Third Anti–SARS-CoV-2 mRNA Dose on Seropositivity in Patients With Lymphoma or CLL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Haematologica
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia
Haematologica 2022 Jun 01;107(6)1454-1459, M Kohn, M Delord, M Chbat, A Guemriche, F Merabet, AL Roupie, N Lombion, H Farhat, T Longval, A Cabannes-Hamy, J Lambert, S Marque-Juillet, V Raggueneau, J Osman, M Spentchian, S Rigaudeau, P Rousselot, C BessonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.